The global market for treating viral respiratory infections is experiencing substantial growth, driven by factors such as the increasing incidence of respiratory infections, advancements in antiviral drug development, and heightened awareness about effective treatments. Key segments within this market include influenza, respiratory syncytial virus (RSV), and other viral infections affecting the respiratory tract. Major pharmaceutical companies are actively involved in developing and marketing antiviral medications to address these infections. However, challenges such as vaccine hesitancy and fluctuating demand for certain vaccines, like GSK's RSV vaccine Arexvy, have impacted market dynamics. Despite these challenges, ongoing research and development efforts continue to drive innovation, aiming to improve treatment efficacy and patient outcomes in the management of viral respiratory infections.
Global Viral Respiratory Infections Treatment Market is valued at USD 57.36 billion in 2023 and is expected to reach USD 108.20 billion by 2031, with a growing CAGR of 8.5% during the forecast period 2024 to 2031.
To know more, visit https://www.databridgemarketresearch.com/reports/global-viral-respiratory-infections-treatment-market
Below are the Top Viral Respiratory Infections Treatment Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
Pfizer Inc.
|
Pfizer Inc. is a global biopharmaceutical company renowned for its extensive portfolio of vaccines, treatments, and therapies across various therapeutic areas. In the viral respiratory infections treatment market, Pfizer is best known for Paxlovid (nirmatrelvir/ritonavir), an oral antiviral treatment for COVID-19. Pfizer also has a significant presence in vaccines, including the Comirnaty COVID-19 vaccine developed in partnership with BioNTech. The company continues to innovate in the antiviral space, focusing on treatments for respiratory viruses, flu, and emerging respiratory pathogens.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In September 2023, Pfizer Inc. announced that after voting in favor of ABRYSVO [Respiratory Syncytial Virus Vaccine], the company's bivalent RSV prefusion F (RSVpreF) vaccine, as a maternal immunization, the Advisory Committee on Immunisation Practises (ACIP) of the U.S. Centres for Disease Control and Prevention (CDC) recommended that the company expand its portfolio of respiratory vaccines. For the first time ever, eligible people can now receive Pfizer immunisations in the autumn to help prevent pneumococcal pneumonia, COVID-19, and RSV. This helped the company to expand its business.
|
|
2.
|
GSK plc.
|
GSK plc. is a global healthcare company focused on pharmaceuticals, vaccines, and consumer healthcare products. GSK has a robust portfolio in the viral respiratory infections treatment market, particularly with its Xofluza (baloxavir marboxil) antiviral treatment for influenza. The company also plays a significant role in vaccine development, with its Fluarix flu vaccine and a range of COVID-19 vaccines. GSK's respiratory disease research spans a variety of viral pathogens, focusing on prevention and treatment for seasonal flu, COVID-19, and other viral infections.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In May 2023, GSK plc. announced that the U.S. Food and Drug Administration (FDA) authorized Arexvy, an adjuvanted respiratory syncytial virus vaccine, for the prevention of Lower Respiratory Tract Disease (LRTD) in people 60 years of age and older. This is the first RSV vaccine for the elderly that has been authorized globally.
|
|
3.
|
Gilead Sciences, Inc.
|
Gilead Sciences is a biopharmaceutical company that focuses on developing treatments for infectious diseases, including viral respiratory infections. Gilead’s expertise lies in antiviral treatments for diseases like COVID-19 and influenza. The company developed Remdesivir (Veklury), an antiviral treatment for COVID-19, which became a key therapy in the pandemic. Gilead continues to develop innovative therapies for respiratory viral infections and is actively involved in developing treatments for emerging respiratory pathogens.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
|
|
4.
|
F. Hoffmann-La Roche Ltd.
|
F. Hoffmann-La Roche Ltd. is a leading global pharmaceutical and diagnostics company with a strong presence in oncology, immunology, and infectious diseases. In the viral respiratory infections treatment market, Roche is well known for its Tamiflu (oseltamivir) antiviral treatment for influenza. The company also played a significant role in the COVID-19 pandemic by offering diagnostic tests and partnering in the development of treatments for viral respiratory infections. Roche continues to innovate in the respiratory space with a focus on developing effective antiviral therapies for both seasonal and novel respiratory viruses.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In May 2023, Hasten Biopharmaceutic Co., Ltd announced that the long-acting, broad-spectrum cephalosporin antibiotic Rocephin's commercial rights in China had been bought from the international healthcare business F.Hoffmann La-Roche Ltd in Switzerland. There was a transition phase between Hasten and Roche after the purchase closed earlier this year. Hasten obtained Roche's rights to commercialize Rocephin in China's mainland as per the terms of the arrangement, along with some intellectual property, such as trademarks, and the authorization to promote the product. This acquisition helped the company to market its drug medications and expand its product line.
|
|
5.
|
Johnson & Johnson Services, Inc.
|
Johnson & Johnson Services, Inc., a subsidiary of Johnson & Johnson, is a leading global healthcare company with a broad portfolio that spans pharmaceuticals, medical devices, and consumer health products. J&J’s contributions to the viral respiratory infections treatment market include its COVID-19 vaccine, developed through the Janssen Pharmaceutical Companies. In addition to its vaccine, J&J has ongoing research and development in antiviral therapies targeting various respiratory viruses. The company continues to advance its portfolio to address viral respiratory infections, focusing on both treatments and vaccines.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In February 2021, Johnson & Johnson Services, Inc. reported that the single-dose COVID-19 vaccine, created by Johnson & Johnson's Janssen Pharmaceutical Companies, has received an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) to prevent COVID-19 in people 18 years of age and older. The EUA's provisions permit vaccination usage while additional information is being obtained. Later in 2021, the company intends to submit a Biologics Licence Application (BLA) to the FDA.
|
Conclusion
The global market for viral respiratory infections treatment is poised for continued growth, driven by the increasing prevalence of respiratory infections and ongoing advancements in antiviral drug development. While challenges such as vaccine hesitancy and varying demand for certain vaccines may influence market dynamics, the sector benefits from continuous research and development efforts aimed at improving treatment outcomes. As pharmaceutical companies focus on innovation and new therapeutic approaches, the market is likely to see greater efficacy in managing viral respiratory infections, leading to improved patient care and market expansion in the coming years.
